About Dompé
Dompé is focussed on the development of treatment solutions for rare and often orphan diseases in areas such as diabetes, organ transplants, ophthalmology and oncology. Its product candidates are either SMW GPCRs modulators or Biotech NCEs. Its portfolio includes Reparixin, a pancreatic islet and lung transplant in phase 3 trials; Ladarixin in phase1 trials for onset type 1 diabetes; rhNGF (recombinant human nerve growth factor) for keratitis (phase 3), retinitis pigmentosa (phase 2) and Glaucoma (phase 1) ; Reparixin in phase 2 for breast cancer and Gabapentin in phase 3 trials for pediatric pain.
- Headquarter Milan, Italy
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dompe Us Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$1.18 M (USD), Grant
Nov 15, 2020
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Dompé
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $1.2M
-
First Round
First Round
(01 Sep 2015)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Grant - Dompé | Valuation |
investors |
|
| Apr, 2020 | Amount | Grant - Dompé | Valuation |
investors |
|
| Sep, 2015 | Amount | Grant - Dompé | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Dompé
Dompé has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Dompé
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Dompé
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dompé Comparisons
Competitors of Dompé
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dompé
Frequently Asked Questions about Dompé
When was Dompé founded?
Dompé was founded in 1940 and raised its 1st funding round 75 years after it was founded.
Where is Dompé located?
Dompé is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
What does Dompé do?
Dompé is focussed on the development of treatment solutions for rare and often orphan diseases in areas such as diabetes, organ transplants, ophthalmology and oncology. Its product candidates are either SMW GPCRs modulators or Biotech NCEs. Its portfolio includes Reparixin, a pancreatic islet and lung transplant in phase 3 trials; Ladarixin in phase1 trials for onset type 1 diabetes; rhNGF (recombinant human nerve growth factor) for keratitis (phase 3), retinitis pigmentosa (phase 2) and Glaucoma (phase 1) ; Reparixin in phase 2 for breast cancer and Gabapentin in phase 3 trials for pediatric pain.
Who are Dompé's investors?
Dompé has 1 investor. Key investors include European Union.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.